NLRP3 and neoplasm: In addition, Theivanthiran et al. have shown that anti-PD1 immunotherapy leads to the upregulation of PD-L1 on tumor cell surface, which converges on NLRP3 activation and downstream release of heat shock protein (HSP) 70.